Ultragenyx Pharmaceutical Inc
Score: Negative (32)
6 days at current score.
Downgraded from Neutral on November 8th 2018
- This company ranked negatively compared to the Healthcare sector despite 2 positive IHS Markit Categories
- Bearish sentiment is moderate and declining
- Economic output in this company's sector is expanding
Short interest | Positive
Short interest is moderate for RARE with between 5 and 10% of shares outstanding currently on loan. However, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on October 12.
ETF/Index ownership | Neutral
ETF activity is neutral. ETFs that hold RARE had net inflows of $1.98 billion over the last one-month. While these are not among the highest inflows of the last year, the rate of inflow is increasing.
PMI by IHS Markit | Positive
According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year.
Credit default swap
CDS data is not available for this security.
Please send all inquiries related to the report to firstname.lastname@example.org.
Charts and report PDFs will only be available for 30 days after publishing.
This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.